BridgeBio Pharma, Inc. BBIO
Set alert
75.30 USD +0.31 +0.41%
As of Nov 3, 11:30 AM ET
75.13 Day range 76.79
60.22 52-week range 93.42
- YTD
- -1.56%
- 1 year
- +21.49%
- Open
- 75.50
- Prev close
- 75.00
- Mkt cap
- 14.66B
- Vol
- 907.72K
- Avg vol
- 2.60M
- EPS
- -3.03
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 75.13
- High
- 76.79
- Forward P/E
- -231.49
- Beta
- 0.94
- Short ratio
- 6.50
- Inst. own
- 99.87%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 23, 2027
- 50-d avg
- 70.27
- 200-d avg
- 72.74
- 1y target
- 107.11
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 107.11 +42.2% upside
Now 75.30
- Target (low)
- 80.00
- Target (mean)
- 107.11
- Target (high)
- 156.00
Ratings (0m) 21 18 buy · 3 hold · 0 sell
- Strong buy4
- Buy14
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 21
- 1 month ago 22
- 2 months ago 22
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.379 | -0.63 – 0.13 | -0.93893 | +59.6% | 302.35M | +96.1% | 5 |
| Next quarter | -0.30 | -0.52 – -0.18 | -0.84 | +64.3% | 336.46M | +73.0% | 3 |
| Current year | -2.25 | -2.41 – -2.09 | -3.78 | +40.5% | 1.09B | +117.9% | 2 |
| Next year | -0.18795 | -2.42 – 1.31 | -2.25 | +91.7% | 1.66B | +52.0% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Oct 30, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 30, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 21, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Oct 19, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Oct 19, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Oct 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 10, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 2, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 1, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Aug 12, 2026 | Truist Securities | Maintained | Buy | Buy |
| Aug 12, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 12, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 11, 2026 | B of A Securities | Maintained | Buy | Buy |
| Aug 11, 2026 | TD Cowen | Maintained | Buy | Buy |
| Aug 11, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 11, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 11, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jul 16, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Jul 13, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 16, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Jun 3, 2026 | Canaccord Genuity | Initiated | — | Buy |
| May 28, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 28, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 26, 2026 | Raymond James | Downgrade | Outperform | Market Perform |
| May 19, 2026 | Citigroup | Initiated | — | Neutral |
| May 11, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 8, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Apr 29, 2026 | Truist Securities | Maintained | Buy | Buy |
| Apr 29, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |